Literature DB >> 9414261

Development and characterization of cationic liposomes conjugated with HVJ (Sendai virus): reciprocal effect of cationic lipid for in vitro and in vivo gene transfer.

Y Saeki1, N Matsumoto, Y Nakano, M Mori, K Awai, Y Kaneda.   

Abstract

Today, nonviral gene transfer vectors attract more attention as a therapeutic strategy for human diseases, because viral vectors such as adenoviral and herpes viral vectors have been proven to have problems, especially in immunogenicity and cytotoxicity. However, the main limitation of nonviral vectors has been low efficiency of gene expression. To overcome this defect, we have developed a new class of transfection vehicles, HVJ-cationic liposomes. The use of the cationic lipid DC-cholesterol facilitates efficient entrapment of negatively charged macromolecules (plasmid DNA, oligodeoxynucleotides, and proteins) and efficient interaction with negatively charged plasma membranes of cultured cells in vitro. Moreover, the fusogenic envelope proteins of hemagglutinating virus of Japan (HVJ) enhance delivery of the enclosed materials into cells. Using firefly luciferase as a marker, we optimized the liposome formula. As a result, we have succeeded in obtaining 100-800 times higher gene expression in vitro than with the conventional HVJ-anionic liposomes. However, in vivo gene transfer experiments have revealed that the use of cationic lipid instead of anionic lipid reduced the transgene expression dramatically in organs such as muscle and liver. We further discovered that the use of anionic liposomes with a viral-mimic king lipid composition increased transfection efficiency by several times in vivo. We conclude that the alternative usage of transfer vectors, for example, HVJ-anionic liposomes for in vivo delivery to extended areas of organs and HVJ-cationic liposomes for in vitro delivery (and possibly for in vivo delivery to a restricted area of organs), is of significance.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9414261     DOI: 10.1089/hum.1997.8.17-2133

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  12 in total

1.  Histone H1-mediated transfection: serum inhibition can be overcome by Ca2+ ions.

Authors:  A Haberland; T Knaus; S V Zaitsev; B Buchberger; A Lun; H Haller; M Böttger
Journal:  Pharm Res       Date:  2000-02       Impact factor: 4.200

Review 2.  Gene therapy for liver diseases: recent strategies for treatment of viral hepatitis and liver malignancies.

Authors:  V Schmitz; C Qian; J Ruiz; B Sangro; I Melero; G Mazzolini; I Narvaiza; J Prieto
Journal:  Gut       Date:  2002-01       Impact factor: 23.059

Review 3.  Nonviral vector gene modification of stem cells for myocardial repair.

Authors:  Husnain K Haider; Ibrahim Elmadbouh; Michel Jean-Baptiste; Muhammad Ashraf
Journal:  Mol Med       Date:  2008 Jan-Feb       Impact factor: 6.354

4.  The study of novel DNA vaccines against tuberculosis: induction of pathogen-specific CTL in the mouse and monkey models of tuberculosis.

Authors:  Masaji Okada; Yoko Kita; Toshihiro Nakajima; Satomi Hashimoto; Hitoshi Nakatani; Shiho Nishimatsu; Yasuko Nishida; Noriko Kanamaru; Yasuhumi Kaneda; Yasushi Takamori; David McMurray; Esterlina V Tan; Marjorie L Cang; Paul Saunderson; E C Dela Cruz
Journal:  Hum Vaccin Immunother       Date:  2012-12-18       Impact factor: 3.452

5.  Treatment of murine Th1- and Th2-mediated inflammatory bowel disease with NF-kappa B decoy oligonucleotides.

Authors:  Stefan Fichtner-Feigl; Ivan J Fuss; Jan C Preiss; Warren Strober; Atsushi Kitani
Journal:  J Clin Invest       Date:  2005-10-20       Impact factor: 14.808

6.  Novel therapeutic vaccines [(HSP65 + IL-12)DNA-, granulysin- and Ksp37-vaccine] against tuberculosis and synergistic effects in the combination with chemotherapy.

Authors:  Yoko Kita; Satomi Hashimoto; Toshihiro Nakajima; Hitoshi Nakatani; Shiho Nishimatsu; Yasuko Nishida; Noriko Kanamaru; Yasuhumi Kaneda; Yasushi Takamori; David McMurray; Esterlina V Tan; Marjorie L Cang; Paul Saunderson; E C Dela Cruz; Masaji Okada
Journal:  Hum Vaccin Immunother       Date:  2012-12-18       Impact factor: 3.452

Review 7.  Liposome-mediated gene therapy in the kidney.

Authors:  Keiichi Ito; Jie Chen; Tomohiko Asano; E Darracott Vaughan; Dix P Poppas; Masamichi Hayakawa; Diane Felsen
Journal:  Hum Cell       Date:  2004-03       Impact factor: 4.174

8.  Novel prophylactic vaccine using a prime-boost method and hemagglutinating virus of Japan-envelope against tuberculosis.

Authors:  Masaji Okada; Yoko Kita; Toshihiro Nakajima; Noriko Kanamaru; Satomi Hashimoto; Tetsuji Nagasawa; Yasufumi Kaneda; Shigeto Yoshida; Yasuko Nishida; Hitoshi Nakatani; Kyoko Takao; Chie Kishigami; Shiho Nishimatsu; Yuki Sekine; Yoshikazu Inoue; David N McMurray; Mitsunori Sakatani
Journal:  Clin Dev Immunol       Date:  2011-03-07

9.  Methods, potentials, and limitations of gene delivery to regenerate central nervous system cells.

Authors:  Arvind Kumar; Tryambak D Singh; Santosh K Singh; Satya Prakash
Journal:  Biologics       Date:  2009-07-13

Review 10.  Gene transfer strategies in tissue engineering.

Authors:  Oliver Bleiziffer; Elof Eriksson; Feng Yao; Raymund E Horch; Ulrich Kneser
Journal:  J Cell Mol Med       Date:  2007 Mar-Apr       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.